{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T18:49:16Z","timestamp":1793558956124,"version":"4.5.0"},"reference-count":25,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.2967\/jnumed.119.233031","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T21:15:44Z","timestamp":1568409344000},"page":"520-526","source":"Crossref","is-referenced-by-count":80,"title":["Cholecystokinin 2 Receptor Agonist <sup>177<\/sup>Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study"],"prefix":"10.2967","volume":"61","author":[{"given":"Christof","family":"Rottenburger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume P.","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"McDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Cachovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Hans","family":"Vija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Schibli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Geistlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Glatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Behe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel R.","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"key":"2021051712144113000_61.4.520.1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0335"},{"key":"2021051712144113000_61.4.520.2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2213-8587(15)00337-X","article-title":"Management of advanced medullary thyroid cancer","volume":"4","author":"Hadoux","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021051712144113000_61.4.520.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5040"},{"key":"2021051712144113000_61.4.520.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4659"},{"key":"2021051712144113000_61.4.520.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0935"},{"key":"2021051712144113000_61.4.520.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4917"},{"key":"2021051712144113000_61.4.520.7","first-page":"1377","article-title":"Cholecystokinin (CCK)-A and CCK-B\/gastrin receptors in human tumors","volume":"57","author":"Reubi","year":"1997","journal-title":"Cancer Res."},{"key":"2021051712144113000_61.4.520.8","doi-asserted-by":"publisher","DOI":"10.1053\/snuc.2002.31028"},{"key":"2021051712144113000_61.4.520.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.106.036020"},{"key":"2021051712144113000_61.4.520.10","first-page":"1012","article-title":"Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys","volume":"46","author":"B\u00e9h\u00e9","year":"2005","journal-title":"J Nucl Med."},{"key":"2021051712144113000_61.4.520.11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1021\/acs.bioconjchem.8b00849","article-title":"Elucidating the structure-activity relationship of the pentaglutamic acid sequence of minigastrin with cholecystokinin receptor subtype 2","volume":"30","author":"Ritler","year":"2019","journal-title":"Bioconjug Chem."},{"key":"2021051712144113000_61.4.520.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1806-0"},{"key":"2021051712144113000_61.4.520.13","doi-asserted-by":"publisher","DOI":"10.1021\/jm101279a"},{"key":"2021051712144113000_61.4.520.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1818-9"},{"key":"2021051712144113000_61.4.520.15","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/s00259-011-2001-z","article-title":"Radiopharmaceutical development of radiolabelled peptides","volume":"39(suppl 1)","author":"Fani","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712144113000_61.4.520.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.207845"},{"key":"2021051712144113000_61.4.520.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.221283"},{"key":"2021051712144113000_61.4.520.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2330-6"},{"key":"2021051712144113000_61.4.520.19","first-page":"1301","article-title":"Automated internal dosimetry research tool using quantitative SPECT for the Lu177 theranostic application","volume":"58","author":"Vija","year":"2017","journal-title":"J Nucl Med."},{"key":"2021051712144113000_61.4.520.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1422-4"},{"key":"2021051712144113000_61.4.520.21","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712144113000_61.4.520.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.138834"},{"key":"2021051712144113000_61.4.520.23","first-page":"567","article-title":"Somatostatin receptors and somatostatin content in medullary thyroid carcinomas","volume":"64","author":"Reubi","year":"1991","journal-title":"Lab Invest."},{"key":"2021051712144113000_61.4.520.24","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"2021051712144113000_61.4.520.25","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/j.1476-5381.2012.01878.x","article-title":"The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat","volume":"166","author":"Barrett","year":"2012","journal-title":"Br J Pharmacol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.119.233031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:47:30Z","timestamp":1621284450000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.119.233031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,1]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.2967\/jnumed.119.233031"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.119.233031","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,13]]}}}